Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2021) 73 PEP8.3 | DOI: 10.1530/endoabs.73.PEP8.3

1Oregon Health and Science University, USA; 2M.F. Vladimirsky Moscow Regional Research Clinical Institute, Russian Federation; 3Novosibirsk State Medical University, Russian Federation; 4Interregional Clinical Diagnostic Center, Russian Federation; 5Northwestern University Feinberg School of Medicine, USA; 6 University of Belgrade, Serbia; 7Antrium Multidisciplinary Medical Clinic, Russian Federation; 8Hospices Civils de Lyon, France; 9Chiasma, Inc., Israel; 10Chiasma, Inc., USA; 11Allegheny General Hospital, USA; 12Samara State Medical University, Russian Federation; 13Krasnoyarsk State Medical University, Russian Federation; 14Leiden University Medical Center, Netherlands; 15Charite Campus Mitte, Germany; 16Cedars Sinai Medical Center, USA


Oral octreotide capsules (OOC; MYCAPSSA®) are approved in the US for individuals with acromegaly who responded to and tolerated treatment with injectable somatostatin receptor ligands (iSRLs). Add-on cabergoline therapy has shown effectiveness in patients previously inadequately controlled with iSRLS.1 The phase 3 MPOWERED trial assessed maintenance of response with OOC compared to iSRLs. Patients receiving OOC and ineligible for randomized controlled treatment (RCT) phase were eligible for a sub-study evaluating combination therapy with cabergoline, a dopamine agonist.


Patients who fail to respond to 80 mg/d OOC for ≥2 weeks during the 26-week Run-in phase, or ineligible to enter the RCT on 80 mg/d OOC, due to inadequate biochemical control (insulin-like growth factor I [IGF-I] ≥1.3 × upper limit of normal [ULN] to <2 × ULN or IGF-I <1.3 × ULN and mean integrated growth hormone [GH] ≥2.5 ng/ml) were eligible for sub-study combination OOC 80 mg/d and cabergoline ≤3.5 mg/week (fixed algorithm) for 36 weeks. End points included categorical changes in IGF-I and mean GH levels at sub-study end and adverse event (AE) incidence and severity. Echocardiogram was performed at sub-study start and every 12 weeks after.


Of 146 patients enrolled in MPOWERED, 14 entered the combination sub-study, 9 having IGF-I ≥1.3 × ULN at sub-study start. Final cabergoline doses were 1 (n = 5), 2 (n = 3), 3 (n = 1), and 3.5 mg (n = 5) with 25.4-week (S.D., 14.1) mean treatment duration. Week 36 IGF-I improved in most patients (n = 12; 85.7%). Of 9 patients with IGF-I ≥1.3 × ULN at sub-study start, 5 (55.6%; 95% CI, 21.2%–86.3%) exhibited IGF-I decreased to predefined responder range ( <1.3 × ULN) by week 36. AE incidence and nature with combined treatment were similar to known octreotide safety profile and acromegaly disease burden. There were no serious AEs or AEs leading to discontinuation of either sub-study drug.


We have shown for the first time the benefit of an all-oral combination treatment for acromegaly and avoidance of injection-related burdens. Addition of cabergoline to OOC yielded biochemical control improvement (IGF-I reduction) in patients inadequately controlled with OOC monotherapy. As both combination and OOC monotherapy safety profiles were similar, adjunctive cabergoline may be helpful in patients with acromegaly who do not achieve adequate biochemical control on OOC alone.

Giustina A, et al. Nat Rev Endocrinol. 2014;10(4):243–248.

Volume 73

European Congress of Endocrinology 2021

22 May 2021 - 26 May 2021

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.